Alphamab Oncology (HKSE:09966) Cash And Cash Equivalents

: HK$1,242.9 Mil (As of Jun. 2023)

View and export this data going back to 2019. Start your Free Trial

Alphamab Oncology's quarterly cash and cash equivalents increased from Jun. 2022 (HK$1,145.67 Mil) to Dec. 2022 (HK$1,193.98 Mil) and increased from Dec. 2022 (HK$1,193.98 Mil) to Jun. 2023 (HK$1,242.87 Mil).

Alphamab Oncology's annual cash and cash equivalents increased from Dec. 2020 (HK$219.69 Mil) to Dec. 2021 (HK$983.62 Mil) and increased from Dec. 2021 (HK$983.62 Mil) to Dec. 2022 (HK$1,193.98 Mil).

Alphamab Oncology Cash And Cash Equivalents Historical Data

The historical data trend for Alphamab Oncology's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alphamab Oncology Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

2,078.47

219.69

983.62

1,193.98

1,187.83

Alphamab Oncology Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash And Cash Equivalents									983.62	1,145.67	1,193.98	1,242.87	1,187.83

Alphamab Oncology Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Alphamab Oncology (HKSE:09966) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Alphamab Oncology Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Alphamab Oncology's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Alphamab Oncology (HKSE:09966) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alphamab Oncology (HKSE:09966) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

3NK:Germany

Address

No. 175 Fangzhou Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215024

Website

https://www.alphamabonc.com

Alphamab Oncology is a clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecifics and protein engineering. The company through its subsidiaries is engaged in discovery, development manufacturing and commercialization of biotherapeutics for cancer treatment.

Alphamab Oncology (HKSE:09966) Headlines

No Headlines